Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Gender: male or female, each sex ratio does not exceed 2/3;~* 18-45 years (including upper and lower limit), the general situation is good;~* Body mass index (BMI) in 19-28 (including upper and lower limit of the range), BW ≥ 50kg (female) and 60kg (male);~* Nearly half of the year, no child care program and agreed to take effective measures to contraception during the study period, women of childbearing age blood pregnancy test was negative;~* Subjects to fully understand the purpose, properties, method and reactions may occur of test drug trials.Voluntarily signed the informed consents, and agreed to abide by the requirements of clinical protocols.~Exclusion Criteria:~* Primary disease in important organs;~* Mental or physical disability;~* Familial hereditary disease;~* Screening supine blood pressure (after 5 minutes of rest) systolic or diastolic blood pressure greater than 90\~140mmHg, beyond the scope of 50\~90mmHg, Or pulse (HR) beyond 50bpm\~100bpm~* Abnormal results of any clinically meaningful physical examination, vital signs, ECG or clinical laboratory;~* History of immunodeficiency diseases, including HIV antibody positive;~* Detection of antibody positive, hepatitis B surface antigen or antibody to hepatitis C / syphilis positive;~* Alcohol and drug abusers;~* Smoking and drinking are (drinking 14 units of alcohol per week: 1 unit = beer 285 ml, or liquor 25 ml, or wine 1 cup. numbers of daily smoking ≥ 5) and / or not smoking and drinking in the test period;~* Any discharge period may affect the study drug, or in the past 3 months participated in any drug clinical trials;~* Before entering the group 4 weeks using any prescription drugs before entering the group, or use of any non prescription drugs within 2 weeks (vitamins, herbal tonics, food additives), or into the group within 2 weeks before taking effect of drug metabolizing enzymes in food, such as grapefruit or grapefruit drink. Can the use of acetaminophen, but must record report in CRF;~* The last 3 months had a history of blood donation or significant blood loss (more than 400ml);~* There are drugs, the clinical significance of the history of food allergy and atopic allergic diseases (asthma, urticaria, eczema dermatitis) or a known drug to test drugs or similar drug allergy test;~* Lactating women, pregnant women or unable to take effective contraceptive measures;~* Researchers believe that the other is not suitable to take the test factors participants.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Kukoamine B Mesilate 0.005mg/kg (Type: EXPERIMENTAL): Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.02mg/kg + Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.04mg/kg +Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.08mg/kg + Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.12mg/kg + Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.24mg/kg + Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.
- Kukoamine B Mesilate 0.48mg/kg + Placebo (Type: EXPERIMENTAL): Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete